$471 Million is the total value of Opaleye Management Inc.'s 39 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CDXS | CODEXIS INC | $42,058,000 | +34.4% | 1,345,000 | 0.0% | 8.92% | +52.7% | |
| HROW | HARROW HEALTH INC | $28,382,000 | -5.0% | 3,285,000 | 0.0% | 6.02% | +7.9% | |
| CYTK | CYTOKINETICS INC | $26,436,000 | +27.5% | 580,000 | 0.0% | 5.61% | +44.8% | |
| STXS | STEREOTAXIS INC | $15,664,000 | +15.2% | 2,526,500 | 0.0% | 3.32% | +30.8% | |
| FBIO | FORTRESS BIOTECH INC | $9,375,000 | -22.4% | 3,750,000 | 0.0% | 1.99% | -11.8% | |
| MGNX | MACROGENICS INC | $7,415,000 | -23.4% | 462,000 | 0.0% | 1.57% | -12.9% | |
| XOMA | XOMA CORP DEL | $7,055,000 | -15.8% | 338,350 | 0.0% | 1.50% | -4.3% | |
| NLTX | NEOLEUKIN THERAPEUTICS INC | $5,048,000 | -33.3% | 1,047,300 | 0.0% | 1.07% | -24.3% | |
| VSTM | VERASTEM INC | $4,766,000 | -33.4% | 2,325,000 | 0.0% | 1.01% | -24.4% | |
| SRRA | SIERRA ONCOLOGY INC | $3,604,000 | -0.8% | 165,778 | 0.0% | 0.76% | +12.5% | |
| AVALO THERAPEUTICS INC | $2,481,000 | -22.0% | 1,459,400 | 0.0% | 0.53% | -11.4% | ||
| BLRX | BIOLINERX LTDsponsored ads | $34,000 | -26.1% | 16,667 | 0.0% | 0.01% | -22.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-10 |
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.